Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
HCV
IDU
OAT
OUD
PWID
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
23 10 2020
23 10 2020
Historique:
received:
22
10
2019
accepted:
31
01
2020
pubmed:
6
2
2020
medline:
28
4
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use-related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown. In this prospective, open-label, observational trial at a harm reduction organization's drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR. Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04). The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use. NCT03221309.
Sections du résumé
BACKGROUND
People who inject drugs have a high prevalence of hepatitis C virus (HCV) and significant disease associated with drug use; however, HCV treatment often occurs in absence of interventions to address opioid use disorder and drug use-related harms. The impact of concurrent initiation of opioid agonist therapy (OAT) on HCV treatment and drug use outcomes is unknown.
METHODS
In this prospective, open-label, observational trial at a harm reduction organization's drop-in center in Washington, DC, 100 patients with chronic HCV infection, opioid use disorder, and ongoing injection drug use were treated with sofosbuvir-velpatasvir for 12-weeks and offered buprenorphine initiation. The primary end point was sustained virologic response (SVR), and secondary end points included uptake of and retention in OAT, change in risk behavior, and determinants of SVR.
RESULTS
Eighty-two patients (82%) achieved SVR, which was not associated with baseline OAT status (P = .33), on-treatment drug use (P >.99), or imperfect daily adherence (P = .35) but was significantly associated with completing 2 or more 28-pill bottles of sofosbuvir-velpatasvir (P < .001) and receiving OAT at week 24 (P = .01). Of 67 patients not already receiving OAT at baseline, 53 (79%) started OAT. At week 24, 68 (68%) patients were receiving OAT. Receipt of OAT was associated with fewer opiate-positive urine drug screens (P = .003), lower human immunodeficiency virus risk-taking behavior scores (P < .001), and lower rates of opioid overdose (P = .04).
CONCLUSIONS
The Novel Model of Hepatitis C Treatment as an Anchor to Prevent HIV, Initiate Opioid Agonist Therapy, and Reduce Risky Behavior study demonstrates high uptake of buprenorphine collocated with HCV treatment, and it shows that concurrent initiation of OAT with HCV treatment can result in high rates of SVR while reducing risks associated with drug use.
CLINICAL TRIALS REGISTRATION
NCT03221309.
Identifiants
pubmed: 32009165
pii: 5721142
doi: 10.1093/cid/ciaa105
pmc: PMC7755091
doi:
Substances chimiques
Antiviral Agents
0
Pharmaceutical Preparations
0
Banques de données
ClinicalTrials.gov
['NCT03221309']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1715-1722Subventions
Organisme : NHLBI NIH HHS
ID : K12 HL143886
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA043396
Pays : United States
Organisme : CLC NIH HHS
ID : HHSN269201400012C
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Lancet Infect Dis. 2018 Feb;18(2):215-224
pubmed: 29153265
N Engl J Med. 2015 Dec 31;373(27):2599-607
pubmed: 26571066
BMJ. 1996 May 4;312(7039):1162
pubmed: 8620161
Ann Intern Med. 2018 Sep 4;169(5):335-336
pubmed: 30007032
N Engl J Med. 2017 Aug 24;377(8):705-707
pubmed: 28834479
Ann Intern Med. 2016 Nov 1;165(9):625-634
pubmed: 27537841
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
J Infect Dis. 2019 Jul 2;220(3):346-349
pubmed: 30941402
N Engl J Med. 2018 Jul 5;379(1):1-4
pubmed: 29972748
AIDS. 1991 Feb;5(2):181-5
pubmed: 2031690
Health Aff (Millwood). 2019 Feb;38(2):287-294
pubmed: 30715966
JAMA Intern Med. 2014 Dec;174(12):1974-81
pubmed: 25347412
Ann Intern Med. 2010 Jun 1;152(11):704-11
pubmed: 20513828
Clin Infect Dis. 2016 Oct 15;63(8):1094-1104
pubmed: 27343545
Ann Intern Med. 2017 Sep 5;167(5):311-318
pubmed: 28785771
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
J Theor Biol. 2019 Nov 21;481:194-201
pubmed: 30452959
Ann Intern Med. 2019 May 7;170(9):594-603
pubmed: 30959528
Ann Intern Med. 2015 Aug 4;163(3):215-23
pubmed: 26120969
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S313-20
pubmed: 15768340
Open Forum Infect Dis. 2018 Jun 07;5(6):ofy076
pubmed: 29977955
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Infect Dis. 2013 Mar;207 Suppl 1:S19-25
pubmed: 23390301
Lancet. 2004 Nov 27-Dec 3;364(9449):1918-9
pubmed: 15566992
Curr Opin HIV AIDS. 2015 Sep;10(5):374-80
pubmed: 26248124